Caribou Biosciences (CRBU) Income towards Parent Company (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Income towards Parent Company data on file, last reported at -$26.3 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$26.3 million, up 38.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$131.7 million (up 19.46% YoY), and the FY2025 annual result was -$148.1 million, up 0.66% from the prior year.
• Income towards Parent Company improved to -$26.3 million in Q1 2026 per CRBU's latest filing, from -$28.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$14.6 million in Q3 2023 and troughed at -$47.6 million in Q2 2025.
• A 5-year average of -$33.2 million and a median of -$31.1 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company surged 44.86% in 2023, then slumped 161.31% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$30.6 million in 2022, then slipped by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then advanced by 26.81% to -$28.5 million in 2025, then increased by 7.64% to -$26.3 million in 2026.
• Business Quant data shows CRBU's Income towards Parent Company at -$26.3 million in Q1 2026, -$28.5 million in Q4 2025, and -$29.4 million in Q3 2025.